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Lung cancer remains the leading cause of cancer death 
in western countries [1]. Recent advances in advanced 
non–small cell lung cancer (NSCLC) therapy have focused 
on selective inhibitors that target driver mutations or genes 
that are critical to tumor growth and proliferation; this 
targeted therapy has led to dramatic clinical responses 
[2, 3]. However, the conventional chemotherapeutic regi-
men continues to be used, particularly as a postoperative 
adjuvant chemotherapy, because adjuvant epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitor 
(TKI) has shown no survival benefit [4]. As a postopera-
tive adjuvant therapy, cisplatin plus vinorelbine (VRB) is 
the standard regimen because adjuvant cisplatin plus VRB 
shows a superior survival benefit in subgroup analyses 
[5]. However, the postoperative 5- year survival rates for 
pathologic stage II–IIIA patients are unsatisfactory, at 
33–61% [6] without adjuvant therapy and 42–52% in a 
group that received adjuvant chemotherapy while lacking 
a residual tumor [7]. Adjuvant chemotherapy has a mod-
est effect toward prolonging survival, with an absolute 
5- year overall survival improvement ranging from 4 to 
15% [8], whereas the response rate to cisplatin plus VRB 
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Abstract
The vinorelbine (VRB) plus cisplatin regimen is widely used to treat non–small 
cell lung cancer (NSCLC), but its cure rate is poor. Drug resistance is the 
primary driver of chemotherapeutic failure, and the causes of resistance remain 
unclear. By focusing on the focal adhesion (FA) pathway, we have highlighted 
a signaling pathway that promotes VRB resistance in lung cancer cells. First, 
we established VRB- resistant (VR) lung cancer cells (NCI- H1299 and A549) 
and examined its transcriptional changes, protein expressions, and activations. 
We treated VR cells by Src Family Kinase (SFK) inhibitors or gene silencing 
and examined cell viabilities. ATP- binding Cassette Sub- family B Member 1 
(ABCB1) was highly expressed in VR cells. A pathway analysis and western blot 
analysis revealed the high expression of integrins β1 and β3 and the activation 
of FA pathway components, including Src family kinase (SFK) and AKT, in 
VR cells. SFK involvement in VRB resistance was confirmed by the recovery 
of VRB sensitivity in FYN knockdown A549 VR cells. Saracatinib, a dual inhibi-
tor of SFK and ABCB1, had a synergistic effect with VRB in VR cells. In 
conclusion, ABCB1 is the primary cause of VRB resistance. Additionally, the 
FA pathway, particularly integrin, and SFK, are promising targets for VRB- 
resistant lung cancer. Further studies are needed to identify clinically applicable 
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or cisplatin plus paclitaxel is 25–28% in advanced NSCLC 
[9].
Drug resistance, whether intrinsic or acquired, is believed 
to underlie treatment failures in over 90% of patients 
with metastatic cancers [10]. Multiple factors affect drug 
sensitivity. Although drug efflux transporters from the 
ATP- binding cassette (ABC) family [11, 12] and class III 
β- tubulin [13] are reportedly involved in VRB resistance, 
their validities as essential factors remain controversial 
[14]. To establish more effective therapies, it is essential 
to elucidate key resistance pathways. Combination therapy 
with cytotoxic drugs and molecular target drugs that inhibit 
the resistance mechanism should be potent candidates for 
overcoming drug resistance and prolonging overall 
survival.
Focal adhesion (FA) pathways, particularly integrins and 
Src family kinase (SFK), play important roles in cancer 
cell survival, invasion, proliferation, and drug resistance 
[15–17]. Although their roles in drug resistance in lung 
cancer are mainly reported in relation to EGFR TKIs 
[18], resistance mechanisms for cytotoxic drugs may also 
be affected by these focal adhesion signals.
To elucidate the mechanism of VRB resistance and 
identify effective drugs in VRB- resistant cancer cells, we 
examined gene expression and protein phosphorylation 
in parental versus induced VRB- resistant (VR) lung cancer 
cell lines. This report shows that ATP- binding Cassette 
Sub- family B Member 1 (ABCB1) and focal adhesion- 
related proteins, particularly SFK and integrin β3, may 
be promising targets for overcoming VRB resistance.
Materials and Methods
Cell culture
Two human non–small cell lung cancer cell lines, NCI- 
H1299 and A549, were maintained in the American Type 
Culture Collection (ATCC)- recommended medium (RPMI 
1640 or Dulbecco’s modified Eagle’s medium (Sigma- 
Aldrich, St. Louis, MO)) supplemented with 10% fetal 
bovine serum (HyClone, Thermo Fisher Scientific K. K. 
Kanagawa, Japan) in standard culturing conditions (5% 
CO2, 100% humidity, 37°C). Mycoplasma negativity was 
confirmed for each cell line before use. VRB- resistant cell 
lines were established using graded VRB concentration 
increases up to 20–100 times the initial concentration as 
previously described [12]. During this process, the cell 
lines were moved into CELLBANKER 1 (Zenoaq, Koriyama, 
Japan) at each resistant stage (H1299 weak resistant, cul-
tured in 5 nmol/L VRB; H1299 moderate resistant, 
50 nmol/L VRB; H1299 VR strong resistant, 500 nmol/L 
VRB; A549 VR, 100 nmol/L VRB) and stored in liquid 
nitrogen until further use.
Compounds
VRB, cisplatin, paclitaxel, docetaxel, and etoposide were 
purchased from Wako Pure Chemical Industries (Osaka, 
Japan). The SFK inhibitor, dasatinib, was purchased 
from Focus Biomolecules (Plymouth Meeting, PA), and 
saracatinib was purchased from Selleck Chemicals 
(Houston, TX). The ABCB1 inhibitor, tariquidar, was 
purchased from Toronto Research Chemicals Inc. 
(Toronto, ON, Canada). Cilengitide (integrin αvβ3 
inhibitor) was purchased from MedchemExpress 
(Monmouth Junction, NJ).
Drug sensitivity assay
Cell viability was determined using Cell Counting Kit- 8 
(Dojindo, Kumamoto, Japan) per the manufacturer’s 
instructions. Cell viability was assessed 96 or 120 h 
after the indicated drug treatment. Three wells were 
used for each drug concentration, and the experiments 
were performed in triplicate. The half- maximum inhibi-
tory concentration (IC50) was calculated using Prism7 
(GraphPad, La Jolla, CA) with a three- parameter sig-
moidal curve fit. The P values for the two- curve com-
parisons were calculated using the extra sum of squares 
F test.
Combination effect
The combination effect of two or three drugs was evalu-
ated based on the combination index (CI) [19, 20] using 
Compusyn software (ComboSyn, Inc. Paramus, NJ). The 
combination effect was defined as follows: CI < 1 indi-
cated a synergistic effect; CI = 1 indicated an additive 
effect; CI > 1 indicated an antagonistic effect.
Gene expression analysis (DNA microarray)
Total RNA was extracted from H1299 parental and VR 
cell lines using an RNeasy Plus mini kit (Qiagen, Valencia, 
CA) per the manufacturer’s instructions. RNA integrity 
was determined with an Agilent 2100 bioanalyzer (Agilent 
Technologies, Santa Clara, CA). The RNA was processed 
with the Ambion WT expression kit (Thermo Fisher 
Scientific K. K.), and GeneChip WT Terminal Labeling 
Kit (Affymetrix, Santa Clara, CA). These samples were 
hybridized to the GeneChip Human Gene 1.0 ST Array 
(Affymetrix), then washed, stained using the Fluidics Station 
450 and scanned with the GeneChip Scanner 3000 
(Affymetrix). The H1299 VR/H1299 parental cell expres-
sion ratio was calculated, and the differential expression 
of a gene was significant if its ratio exceeded 2. A pathway 
analysis was performed on the differentially expressed 
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genes using GeneSpring GX (Agilent Technologies) and 
WikiPathways.
Quantitative reverse transcription- PCR 
(qRT- PCR)
Total RNA from H1299 parental, H1299 VR, A549 parental, 
or A549 VR cells was reverse transcribed to cDNA using 
Ready- To- Go You- Prime First- Strand Beads (GE Healthcare 
Life Sciences, Pittsburgh, PA) per the manufacturer’s instruc-
tions. For qRT- PCR, each cDNA was diluted to 10 ng/μL, 
and 2 μL of cDNA was mixed with the THUNDERBIRD 
Probe qPCR Mix (Toyobo, Osaka, Japan) and TaqMan Gene 
Expression Assay probe/primer set (Thermo Fisher Scientific 
K. K.). The reactions were run using a StepOnePlus Real- 
Time PCR System (Thermo Fisher Scientific K. K.). The 
comparative Ct (ΔΔCt) method was used to determine rela-
tive expression using β- actin (ACTB) as the control gene 
[21]. Each sample was run in triplicate. The following TaqMan 
probes were used: ACTB (Hs01060665_g1), integrin beta 3 
(ITGB3, Hs01001469_m1), ATP- binding cassette, subfamily 
B, member 1 (ABCB1, Hs00184500_m1), v- src avian sarcoma 
viral oncogene homolog (c-SRC, Hs01082246_m1), protein 
tyrosine kinase 2 (FAK, Hs01056457_m1), FYN (FYN, 
Hs00941600_m1), integrin- linked kinase (ILK, Hs00177914_
m1), and prominin 1 (PROM1, CD133, Hs01009257_m1).
Western blot analysis
Total cell lysates were resolved by 4–15% SDS- PAGE 
and transferred onto PVDF membranes. Primary antibod-
ies to SFK, pTyr416 SFK, ITGB3, AKT, and pSer437 AKT 
were purchased from Cell Signaling Technology (Danvers, 
MA). ITGB1 and FAK were purchased from Merck 
Millipore (Darmstadt, Germany). FYN and pSer21 FYN 
were purchased from ABclonal Biotechnology (Woburn, 
MA). pTyr397 FAK was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). β- actin was purchased 
from Sigma- Aldrich (St Louis, MO). Following an over-
night incubation with the primary antibody, membranes 
were incubated with horseradish peroxidase- conjugated 
secondary antibodies (Jackson ImmunoResearch, West 
Grove, PA), then visualized using the EzWestLumi Plus 
detection kit (Atto, Tokyo, Japan), and luminescence was 
detected using the LuminoGraph II imaging system (Atto).
Drug efflux assay
ABCB1- mediated drug efflux was measured using Cell- Based 
Assay Calcein AM (Cayman Chemicals, Ann Arbor, MI) per 
the manufacturer’s instructions and a previous report [22]. 
The nuclei were counterstained with Hoechst 33342 (Dojindo). 
The fluorescence of each dye was assessed with an ArrayScan 
VTI (Thermo Fisher Scientific K. K.). Calcein fluorescence 
in the perinuclear ring was calculated using the HCS Studio 
2.0 Client Software (Thermo Fisher Scientific K. K.).
Gene silencing (siRNA)
The custom- made annealed double- strand siRNAs were 
purchased from Japan Bio Services Co., LTD (Saitama, 
Japan). The RNA sequences were as follows: si- c-SRC#1, 
forward GGUGUCUUAAUACUGUCCUTT, reverse AGGA 
CAGUAUUAAGACACCTT; si- c-SRC#2, forward CCUUC 
CUGGAGGACUACUUTT, reverse AAGUAGUCCUCCAG 
GAAGGTT; si- FYN#1, forward GAAAAAUUUCAAAUAU 
UGATT, reverse UCAAUAUUUGAAAUUUUUCTT; si- FYN#2, 
forward CCCUGUACGGGAGGUUCACAAUCAATT, rev-
erse UUGAUUGUGAACCUCCCGUACAGGGTT; si- ITGB3#1 
forward UGUGUGGAGUGUAAGAAGUTT, reverse ACU 
UCUUACACUCCACACATT; si- ITGB3#2, forward CCAG 
AUGAUUCGAAGAAUUTT, reverse AAUUCUUCGAAUC 
AUCUGGCC; and si- Control, forward GCGCGCUUUGUA 
GGAUUCGTT, reverse CGAAUCCUACAAAGCGCGCTT. 
Mission siRNA for human ABCB1 were purchased from 
Sigma- Aldrich (si- ABCB1#1 SASI_Hs01_00087519, si- 
ABCB1#2 SASI_Hs01_00087520). The siRNA (12.5 μl of a 
20 μM solution) was transfected into VR cells that were 
approximately 60% confluent in 6- well dishes with 5 μL 
Lipofectamine 2000 and 500 μL Opti- MEM. For drug sen-
sitivity assays, cells were detached from dishes with trypsin 
after 24 h of transfection, and 2,000 cells were seeded into 
each well of a 96- well dish. After a 4- h incubation, various 
VRB concentrations were added to the wells, and cell viability 
was determined after 120 h.
Src- Tyr416 immunohistochemistry of clinical 
specimens
Immunohistochemistry (IHC) was performed to measure 
pTyr416 SFK expression in operative FFPE tissue samples 
from sixty lung cancer patients who had undergone lung 
cancer resections and adjuvant VRB plus cisplatin chemo-
therapy between December 2002 and January 2007 at 
our institute. The characteristics and prognoses of these 
patients have been previously reported [23]. The study 
protocol was approved by the ethics committee of our 
university (G0028- 5). The slides were stained with the 
pTyr416 SFK rabbit monoclonal antibody (Cell Signaling 
Technology) and VECTASTAIN Elite ABC HRP Kit 
(Vector Laboratories, Burlingame, CA) per the manufac-
turer’s protocol. Each specimen was categorized as negative 
or positive. Time- to- event curves were estimated using 
the Kaplan–Meier method, and differences were evaluated 
with the log- rank test. Statistical analyses were performed 
using JMP12 software (SAS Institute Inc. Cary, NC).
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Results
Characteristics of VRB- resistant cell lines
The VRB IC50 for the VR cells exceeded 100 times that 
for the parental cells (Fig. 1A). H1299 VR cells had a 
cross- resistance to paclitaxel (PAC), docetaxel (DOC), and 
etoposide (VP- 16) and were sensitive to cisplatin (CDDP) 
(Fig. 1B). The H1299 VR cell growth rate in fetal bovine 
serum (FBS)- free medium compared with that in FBS- 
containing medium was higher than that of the H1299 
parental cells (Fig. 1C). A qRT- PCR analysis of a cancer 
stemness marker, CD133 [24], showed significant upregula-
tion compared with the corresponding parental cells 
(Fig. 1D). But, no other generally accepted cancer stemness 
markers were not significantly upregulated.
Gene expression comparison of parental 
versus VR cells by microarray and qRT- PCR
A microarray- based comparison of H1299 parental and 
H1299 VR cells revealed that 205 of 23,230 genes were 
highly expressed (fold change >2) in H1299 VR cells. 
ABCB1 was the most highly expressed gene in H1299 VR 
cells and a pathway analysis of the 205 genes indicated 
that the FA pathways were significant (P = 0.00086). High 
expression of these genes was confirmed by qRT- PCR 
(Fig. 2A).
Activation of drug efflux and FA pathway in 
H1299 VR cells
Efflux assays revealed an enhancement of ABCB1- mediated 
drug efflux in H1299 VR cells (Fig. 2B). And drug efflux 
in H1299 VR cells was reduced both by an ABCB1 inhibi-
tor, tariquidar (TQD), or ABCB1 silencing, respectively 
(Fig. 2B).
We subsequently examined the expression and activa-
tion levels of focal adhesion- related proteins by Western 
blot. Integrins β1 and β3 were highly expressed in VR 
cells relative to parental cells. The high expression of 
pTyr416 SFK, pSer21 FYN, pTyr397 FAK, and pSer437 
AKT indicated FA pathway activation in VR cells 
Figure 1. Characteristics of H1299 and A549 VR cells. (A) H1299 
parental and VR (weak, moderate, and strong resistant) cell viabilities in 
response to VRB. H1299 parental and VR cells were treated for 96 h 
with increasing concentrations of VRB. Cell viability was determined 
using the WST- 8 assay and is shown as a percentage of the value of the 
untreated cells. The sigmoid curves were drawn using Prism software. 
Experiments were performed in triplicate. (B) The IC50 values for VRB, 
PAC, DOC, VP- 16, and CDDP in H1299 parental and VR cells. Cell 
viability in response to PAC, DOC, VP- 16, and CDDP was measured as 
described for VRB. Experiments were performed in triplicate. The IC50 
values were calculated using Prism software. The error bars show the 
95% CI. * P < 0.05 relative to the control (extra sum of squares F test). 
PAC, paclitaxel; DOC, docetaxel; VP- 16, etoposide; CDDP, cisplatin. (C) 
H1299 parental and VR cell growth rates in FBS- free medium. H1299 
parental and VR cell viabilities were determined after 96- h incubations 
in FBS- free medium. Results are shown as the ratio to cells that were 
grown in FBS- containing medium and as the mean ± SEM. (D) Relative 
mRNA expression of CD133 in H1299 and A549 VR cells. Results are 
shown as the fold change of CD133 expression relative to the 
corresponding parental cell line and as the mean ± 95% CI.
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(Fig. 2C). Integrin β3, pTyr416 SFK, and pSer21 FYN 
expression incrementally increased with the VR resistance 
level.
Activation of SFK in human lung cancer 
samples
The patient characteristics are shown in the Table 1. The 
cancer cells were stained with a pTyr416 SFK antibody 
in a peripheral or cytoplasmic manner (Fig. 3A). Of the 
60 operative samples, 34 samples were negative, and 26 
samples were positive. The patient prognoses for each 
group relative to pTyr416 SFK expression are shown in 
Figure 3B; the pTyr416 SFK expression status did not 
show a correlation with patient prognosis. Furthermore, 
the staining pattern (peripheral or cytoplasmic) did not 
affect survival (data not shown).
The effect of ABCB1 and SFK knockdown by 
siRNA on VRB sensitivity
The knockdown efficiency was determined by qRT- PCR 
using RNA that was extracted from the transfected cells 
48 h after the transfection (Fig. 4A). Effects on protein 
expression were also assessed in si- ABCB1#1 treated cells 
(120 h after transfection, Fig. S1A). We used si- ABCB1#1, 
si- c-SRC#2, si- FYN#2, and si- ITGB3#2 for further experi-
ments. The A549 VR cells showed more effective inhibition 
than the H1299 VR cells. The VRB IC50 for the si- ABCB1#1 
treated H1299 VR cells was decreased, however, it was 
not fully recovered to that of parental cells (Fig. S1B). 
The VRB IC50 for the si- FYN#2- treated A549 VR cells 
was significantly decreased compared with that of the 
control (P = 0.0002). On the other hand, c-SRC and 
ITGB3 silencing did not show prominent VRB IC50 
decreases (Fig. 4B). These results indicate that SFK 
Figure 2. Gene and protein expression comparisons for parental versus VR cells. (A) Relative mRNA expression of ABCB1, AKT, FAK, c-SRC, FYN, ILK, 
and ITGB3 in H1299 and A549 VR cells. Results are shown as the fold change in gene expression relative to the corresponding parental cell line and 
as the mean ± 95% CI. (B) Calcein fluorescence in H1299 parental and VR cells. After a 30- min incubation with tariquidar (TQD) or DMSO, Calcein 
AM was added to the cells. After 30 min, fluorescent images were obtained with the BZ- 9000 (Keyence Corporation, Osaka, Japan). Nuclei were 
counterstained with Hoechst 33342. Images were merged using ImageJ. In H1299 VR si- ABCB1#1 and si- Control, transfection of siRNA was done 
120 h before. Calcein (green), Hoechst 33342 (blue), and phase contrast images (gray) are shown.(C) Western blot analysis of whole- cell lysates from 
H1299 parental and VR (W: Weak, M: Moderate and S: Strong resistant) cells. Membranes were blotted with total ITGB1, ITGB3, pTyr416 SFK, total 
SFK, pSer21 FYN, total FYN, pTyr397 FAK, total FAK pSer437 AKT, and total AKT antibodies; β- actin was used to confirm equal protein loading.
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(specifically FYN) plays pivotal roles in VRB resistance. 
However, the knockdown of FYN in the H1299 VR cells 
did not significantly restore VRB sensitivity (Fig. S1C).
Effect of ABCB1, SFK, and an integrin 
inhibitor on VR cells
Although a 96- h exposure to 300 nmol/L tariquidar alone 
did not produce H1299 VR cell toxicity (Fig. 5A), H1299 
VR cells that were treated with as little as 15 nmol/L 
tariquidar recovered their VRB sensitivity (Fig. 5B).
We subsequently aimed to inhibit SFK activation using 
dasatinib (DAS), an SFK inhibitor. However, the H1299 
VR cells had cross- resistance to dasatinib (Fig. 5C), and 
100 nmol/L dasatinib did not effectively inhibit SFK activa-
tion (Fig. 5D) nor was it effective toward VRB sensitivity 
in H1299 VR cells (Fig. 5E). Because dasatinib is also a 
substrate for ABCB1 [25], we combined tariquidar and 
dasatinib to inhibit efflux and improve the effect of dasat-
inib. By combining 15 nmol/L tariquidar with 100 nmol/L 
dasatinib, we effectively inhibited SFK activation and reduced 
H1299 VR cell survival. The combination of 100 nmol/L 
VRB with 100 nmol/L dasatinib plus 15 nmol/L tariquidar 
almost completely inhibited cell survival (Fig. 5D and E).
We next used saracatinib (SAR), a specific inhibitor of 
SFK that also inhibits ABCB1 [26]. The efflux assay revealed 
a concentration- dependent ABCB1- mediated calcein efflux 
inhibition (Fig. 5F). Consistent with these results, H1299 
VR cells did not show cross- resistance to saracatinib; the 
IC50 for saracatinib in H1299 VR cells was notably lower 
than that in H1299 parental cells (Fig. 5C). The effective 
inhibitory dose for ABCB1 (2 μmol/L saracatinib) also 
remarkably inhibited SFK activity (Fig. 5G). The 1 μmol/L 
saracatinib plus 1 μmol/L VRB combination more effec-
tively inhibited H1299 VR and A549 VR cell viability 
than saracatinib or VRB alone. The combination index 
(CI) values for VRB plus saracatinib in the H1299 VR 
and A549 VR cells indicated that the concomitant use of 
Table 1. Characteristics of the patients included in this study.
Characteristic Number of 









Squamous cell carcinoma 21 (35)
Large cell carcinoma 3 (5)
Adenosquamous cell carcinoma 1 (2)
Pleomorphic carcinoma 1 (2)
Pathological stage (UICC, 7th edition) (%)
Stage IIA 21 (35)
Stage IIB 8 (13)
Stage IIIA 31 (52)
Patients who completed cycles (%)
Cycle 1 58 (97)
Cycle 2 55 (92)
Cycle 3 50 (83)
Cycle 4 28 (47)
Figure 3. pSFK expression in human lung cancer samples and its 
correlation with survival. (A) Representative Immunohistochemistry 
images of lung adenocarcinoma sections with anti- pTyr416 SFK. Tumor 
cells show peripheral (left) or cytoplasmic staining (right).(B, C) Kaplan–
Meier curves for overall survival and disease- free survival per pTyr416 
SFK expression. Log- rank P values were calculated using JMP software.
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VRB and saracatinib had synergistic effects on the VR 
cells (Fig. 5H).
Then we tested the effectiveness of cilengitide (CIL), 
an integrin αvβ3 inhibitor. Because cilengitide, a cyclic 
RGD pentapeptide, targets the extracellular domain [27], 
we predicted that ABCB1 activation would not alter its 
effectiveness. As expected, the IC50 of cilengitide in H1299 
VR cells was significantly lower than the IC50 in H1299 
parental cells (Fig. 5C). The combination index for VRB 
plus cilengitide and cilengitide, VRB plus saracatinib 
showed synergism in H1299 VR cells (Fig. 5H).
Discussion
VRB is a common chemotherapeutic agent in lung cancer 
therapies, particularly in postoperative chemotherapy. 
However, its narrow applicability to other cancer types 
has limited the number of reports that address VRB resist-
ance relative to other drugs. Several reports have shown 
that SFK inhibition potentiates the anticancer activity of 
paclitaxel [28, 29]. Although VRB and paclitaxel belong 
to different drug families, both drugs affect the same 
target, the microtubule. It is conceivable that VRB has a 
similar resistance mechanism to that of paclitaxel. Forest 
et al. [30] reported decreased activation of paxillin in 
Figure 4. c-SRC, FYN, and ITGB3 silencing by siRNA and its effect on 
VRB sensitivity. (A) The c-SRC gene in H1299 VR and A549 VR cells was 
knocked down with siRNA transfections (si- c-SRC#1 and si- c-SRC#2). 
The inhibitory effects on c-SRC gene expression were measured by qRT- 
PCR. The relative mRNA expression of c-SRC in si- c-SRC#1- or si- c-
SRC#2- transfected cells is shown as the fold change in c-SRC expression 
relative to the corresponding si- Control cell line and as the mean ± 95% 
CI. The inhibitory effects of the FYN (si- FYN#1 and si- FYN#2), ITGB3 (si- 
ITGB3#1 and si- ITGB3#2), or ABCB1 (si- ABCB1#1 and si- ABCB1#2) 
gene silencing are also shown. (B) A549 VR siRNA- transfected cell 
viability. A549 VR cells that were transfected with siRNA (c-SRC#2, 
FYN#2, ITGB3#1, or Control) were treated for 120 h with increasing 
concentrations of VRB. The data from the cell viability assay (WST- 8 
assay) are expressed as a percentage of the value of the untreated cells. 
The IC50 was calculated using Prism software. Experiments were 
performed in triplicate.
Figure 5. Recovery of VRB sensitivity through ABCB1 or SFK inhibition. (A) Cell viability of H1299 VR cells treated with tariquidar. H1299 VR cells were 
treated for 96 h with increasing concentrations of tariquidar. Cell viability is shown as a percentage of the value of the untreated cells. The IC50 was 
not calculated due to the lack of low viability data. (B) The IC50 values for VRB in H1299 VR cells that were treated with DMSO or tariquidar. H1299 
VR cells were treated for 96 h with increasing concentrations of VRB and 15 nmol/L tariquidar or DMSO. The IC50 values were calculated using Prism 
software. The error bar shows the 95% CI. (C) IC50 values for dasatinib, saracatinib, and cilengitide in H1299 parental and VR cells. Cells were treated 
for 96 h with increasing concentrations of dasatinib, saracatinib, or cilengitide. The IC50 was calculated using Prism software. * P < 0.05, ** P < 0.01. 
(D) Western blot analysis of whole- cell lysates from H1299 VR cells. Cells were treated with dasatinib or dasatinib plus tariquidar for 3 h, and cell 
lysates were collected. Membranes were blotted with the pTyr416 and total SFK antibodies. (E) Cell viability in response to VRB for H1299 VR cells 
that were treated with tariquidar and/or dasatinib. Cells were treated for 96 h with increasing concentrations of VRB plus 100 nmol/L dasatinib and/
or 15 nmol/L tariquidar. The cell viabilities from the WST- 8 assays are expressed as the percentage of the value for untreated cells, and the sigmoid 
curves were drawn by Prism software. Determinations were performed in triplicate. (F) Calcein fluorescence intensities in H1299 VR cells. Calcein 
fluorescence after incubations with tariquidar, saracatinib, dasatinib, or DMSO was detected with ArrayScan VTI. Perinuclear fluorescence was 
quantified using HCS Studio 2.0 Client Software. (G) Western blot analysis of whole- cell lysates from H1299 VR cells. Cells were treated with 
saracatinib for 3 h. Membranes were blotted with the pTyr416 and total SFK antibodies. (H) Cell viability of H1299 VR and A549 VR cells that were 
treated with 1 μmol/L VRB and/or 1 μmol/L saracatinib and/or 3.16 μmol/L cilengitide. The data from the cell viability assays (WST- 8 assay) are 
expressed as a percentage of the value for the untreated cells. The combination index (CI) was calculated using Compusyn software. TQD, tariquidar; 
DAS, dasatinib; SAR, saracatinib; CIL, cilengitide.
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A549 cells that were cocultured with VRB; the dephos-
phorylation of paxillin functions as an apoptotic signal. 
Consistently, SFK activation, which activates paxillin, results 
in cell survival.
Although v- Src, which contains a truncating mutation 
among its regulatory C- terminal tyrosine residues, is an 
oncogene, SFK is prevalent in tumor progression and in 
maintaining the neoplastic phenotype; it is not involved 
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in tumor initiation or growth [31]. The SFK function in 
cancer cells is independent of its mutation status, c- SRC 
activation by oncogenic mutations has not been detected 
in most cancers [32]. In the context of acquired resist-
ance, de novo mutations would not be the main cause 
of chemo- resistance because clinically relevant mutations 
after chemotherapy are reportedly rare [33]. The phos-
phorylation status of SFK is controlled by the functional 
or activation changes of its regulatory proteins, such as 
integrins or receptor tyrosine kinases (RTKs). We focused 
on integrin β3 as an upstream regulator of SFK because 
VR cells showed high integrin β3 expression. While the 
ITGB3 knockdown did not alter VRB sensitivity in VR 
cells, cilengitide showed an inhibitory effect on VR cells. 
These results indicate that integrin β3 is not an independ-
ent activator of SFK; other transmembrane proteins, such 
as integrins αvβ5 and α5β1, might also affect SFK activa-
tion in VR cells, because cilengitide targets integrins αvβ3, 
αvβ5, and α5β1 [27]. Moreover, SFK interacts with numer-
ous genetic and signaling pathways, including the EGFR, 
Janus- activated kinase (JAK)/signal transducers and activa-
tors of transcription (STAT), and vascular endothelial 
growth factor (VEGF) pathways [32]. Further studies are 
needed to elucidate the roles of these interactions in VRB 
resistance.
SFK proteins are comprised of nine family members—c- 
Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk, and Yrk. In this 
study, FYN expression was higher than c-SRC expression, 
and FYN knockdown restored VRB sensitivity in A549 
VR cells; c-SRC knockdown showed little effect. This result 
suggested a higher importance for FYN in VRB resistance, 
although technical problems may have influenced the 
results. Specifically, our siRNA for FYN (si- FYN#2) inhib-
ited gene expression more effectively than si- c-SRC#2. As 
we only examined the c-SRC and FYN knockdown accord-
ing to both the high expression of the Fyn gene in VR 
cells and the previous report which showed the effect of 
c-SRC and FYN on EGFR- TKI sensitivity [34], the dif-
ferences between these family members were not well 
described.
Results of our report showed difference in effect of 
FYN knockdown between H1299 VR and A549 VR cells. 
Depending on the other results of FA pathway activation 
and SFK inhibitors, we considered FYN also have an 
important role in VRB resistance in H1299 VR cells, 
however, the effect of siRNA was limited because the 
cells with higher growth rate, like H1299, showed lower 
efficiency in gene knockdown [35, 36].
In addition to SFK, SFK inhibitors have multiple targets, 
such as Abl, EGFR, PDGFR, and c- Kit (Table S1). Among 
these targets, inhibition of EGFR should affect the survival 
of VRB- treated cancer cells, because Pirker et al. reported 
longer survival in addition of cetuximab to CDDP plus 
VRB [37]. The effects of dasatinib or saracatinib on EGFR 
inhibition are not described in this report, but those effects 
seem to be limited because both H1299 and A549 do 
not have EGFR mutation. We used saracatinib to inhibit 
both SFK and ABCB1, which are the two main factors 
in VRB resistance. Saracatinib may be a strong candidate 
drug for patients with relapse after VRB therapy. However, 
at 2 μmol/L saracatinib, which effectively inhibited SFK 
and ABCB1 activities in VR cells, the drug concentration 
was remarkably higher than the serum concentration in 
patients from a previous study who took once- daily 175- 
mg doses of saracatinib [38]. This finding may be a 
causative factor in the negative clinical trial results for 
NSCLC [39] and other malignancies [40–43].
Our IHC results revealed no significant correlation 
between pSFK (Tyr416) expression and patient prognosis. 
Zhang et al. reported that pSFK expression was not asso-
ciated with the pathological disease stage or survival in 
patients with stage I- II NSCLC who had undergone lung 
resections [44]. Laurie et al. reported no correlation 
between Src protein expression and patient outcome in 
a phase II trial of saracatinib in previously treated advanced 
NSCLC patients; phospho- Src was not assessed [39]. These 
reports claimed that pSFK expression was not a clinically 
valuable biomarker for prognostic predictions. According 
to our results, phospho- FYN expression may predict the 
prognosis, but we could not find reliable phospho- Fyn 
specific antibody for IHC. Additionally, our results revealed 
post- VRB treatment SFK activation. However, our clinical 
samples were obtained during the surgeries of patients 
who had not received chemotherapy or radiotherapy. 
These samples did not reflect the acquisition of postch-
emotherapy VRB resistance. However, we had better know 
the information whether patient’s tumor has innate chemo- 
resistance (not acquired resistance) before treatment, 
especially in the setting of postoperative adjuvant 
chemotherapy.
Cancer stem cells are a reported cause of drug resist-
ance and poor prognosis [45]. The VR cells in our study 
show several characteristics that are associated with cancer 
stemness. Desgrosellier et al. reported that the integrin 
αvβ3–Src unit promotes anchorage- independence[46]. 
Integrin β3 also drives tumor stemness [15]. We previ-
ously reported that CD133, a cell surface marker that is 
used to isolate cancer stem cells, is a statistically significant 
factor for predicting a poor lung adenocarcinoma prog-
nosis [24], and Su et al. reported that CD133 activates 
integrin- Src- Akt signaling [47]. Although our study did 
not address the relationship between SFK- related drug 
resistance and cancer stemness, it is possible that the 
acquisition of drug resistance and cancer stemness share 
the same root cause and that SFK may be a target for 
eradicating cancer stem cells.
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In conclusion, we have described both of the ABCB1 
overexpression and activation of the FA pathway, and its 
availability for inhibition in VRB- resistant cells. Moreover, 
saracatinib and cilengitide are particularly promising inhibi-
tors of ABCB1- accelerated cells. However, several discrep-
ancies between the laboratory results and clinical outcomes 
remain. Further studies are needed to identify clinically 
applicable target drugs and biomarkers that will improve 
disease prognoses and predict the therapeutic efficacy of 
SFK inhibition.
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